Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Employees - 72,
CEO - Dr. Lishan Aklog M.D.,
Sector - Healthcare,
Country - US,
Market Cap - 127.21M
Altman ZScore(max is 10): -10.96, Piotroski Score(max is 10): 4, Working Capital: $1624000, Total Assets: $30715000, Retained Earnings: $-203766000, EBIT: -45503000, Total Liabilities: $25324000, Revenue: $4345999
- Current Price $1.21 - Analyst Target Price $3.00| Ticker | LUCD |
| Index | - |
| Curent Price | 1.21 |
| Change | 11.01% |
| Market Cap | 127.21M |
| Average Volume | 939.88K |
| Income | -53.02M |
| Sales | 4.35M |
| Book Value/Share | -0.78 |
| Cash/Share | 0.21 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 72 |
| Moving Avg 20days | -15.00% |
| Moving Avg 50days | -13.20% |
| Moving Avg 200days | 22.36% |
| Shares Outstanding | 63.07M |
| Earnings Date | Mar 24 BMO |
| Inst. Ownership | 4.29% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | 29.24 |
| Price/Book | - |
| Price/Cash | 5.69 |
| Price/FCF | - |
| Quick Ratio | 1.03 |
| Current Ratio | 1.07 |
| Debt/Equity | 3.94 |
| Return on Assets | -157.04% |
| Return on Equity | -2956.43% |
| Return on Investment | -737.38% |
| Gross Margin | -90.20% |
| Ops Margin | -1059.66% |
| Profit Margin | -1220.09% |
| RSI | 42.45 |
| BETA(β) | 1.36 |
| From 52week Low | 92.03% |
| From 52week High | -32.78% |
| EPS | -1.07 |
| EPS next Year | -0.33 |
| EPS next Qtr | -0.16 |
| EPS this Year | 29.75% |
| EPS next 5 Year | 40.08% |
| EPS past 5 Year | -54.43% |
| Sales past 5 Year | 119.69% |
| EPS Y/Y | 15.03% |
| Sales Y/Y | 79.00% |
| EPS Q/Q | 22.71% |
| Sales Q/Q | 15.10% |
| Sales Surprise | -16.19% |
| EPS Surprise | -6.74% |
| ATR(14) | 0.15 |
| Perf Week | -3.20% |
| Perf Month | -19.33% |
| Perf Quarter | 42.86% |
| Perf Year | 48.47% |
| Perf YTD | 47.80% |
| Target Price | 3.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer